Immune-guided prevention of cytomegalovirus infection after kidney transplant
Compares immune-guided prevention with routine preventive treatment against CMV infection in kidney transplant recipients.
Key facts
- Who runs it
- Centre Hospitalier Universitaire Rouen
- Where
- France2 sites in 1 countryChoose a country to see its sites
- Registry title
- Effectiveness of a preventive strategy for cytomegalovirus infection guided differently from a universal prophylactic strategy in kidney transplant patients - CYTOPREV
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 144 people, planned
- Started
- 14 Aug 2024
- Planned end
- 28 Mar 2026
- Type of study
- Interventional
- Record updated
- 26 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who had a kidney transplant 1 to 12 days ago and carry past CMV (cytomegalovirus) infection. It compares two ways of preventing CMV infection.
- Age
- 18 to 75 years
- Sex
- All sexes
- Disease stage
- Kidney transplant done 1 to 12 days ago. No active CMV infection.
- Earlier treatment
- Must have received Basiliximab, a non-depleting immune-lowering drug, before the transplant. People who received antithymoglobulins cannot join.
- Biomarker or test result
- CMV antibodies (IgG) in the blood on the day of transplant: IgG threshold =6 AU/mL, tested before the transplant.
Main reasons for not taking part
- Active CMV infection (CMV DNAemia ≥ 305 IU/mL in the blood)
- Allergy to valganciclovir, ganciclovir, aciclovir or valaciclovir
- Very low blood counts: neutrophils < 500/mm3, platelets < 25,000/mm3 or hemoglobin < 8g/dl
- Pregnant or breastfeeding, or not using proven birth control
- Taking part in another drug trial
This trial only enrols participants who have had an organ transplant. The registry sentence this rests on: Renal transplant patient for 1 to 12 days
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- 18 years ≤ Age ≤ 75 years
- Renal transplant patient for 1 to 12 days
- CMV seropositivity on the day of transplantation: IgG threshold =6 AU/mL CMIA CMV IgG, Architect i4000 (Abbott)) (Serology performed on D0, before the transplant)
- Non-depleting inducing immunosuppressive treatment (Basiliximab) (implementation before the transplant)
- Affiliation to a social security scheme
- Patient having read and understood the information letter and signed
- For women: - Woman of childbearing potential using effective contraception (Cf. CTFG) (estrogen-progestin or intrauterine device or tubal ligation) for at least 1 month and a negative β-HCG blood pregnancy test at inclusion, throughout the duration of study treatment and for at least 30 days after stopping study treatment. - Postmenopausal woman: confirmatory diagnosis (non-medically induced amenorrhea for at least 12 months before the inclusion visit) - Surgically sterile woman (absence of ovary and/or uterus)
- Pour les hommes : - Stérilité chirurgicale, ou - Contraception mécanique (préservatif) pendant toute la durée du traitement à l’étude et pendant au moins 90 jours après la fin du traitement à l’étude, ou - Avec une partenaire en âge de procréer prenant une contraception efficace (Cf. CTFG) (oestro-progestatifs ou dispositif intra-utérin ou ligature de trompes) depuis au moins 1 mois à l’inclusion, pendant toute la durée du traitement à l’étude et pendant au moins 90 jours après l’arrêt du traitement, ou - Avec une partenaire ménopausée : diagnostic de confirmation (aménorrhée non médicalement induite depuis au moins 12 mois avant la visite d’inclusion), ou - Avec une partenaire chirurgicalement stérile (absence d’ovaire et/ou d’utérus)
Who cannot take part
- Active CMV infection (detectable CMV DNAemia - peripheral CMV DNAemia ≥ 305 IU/mL)
- Patient with hypersensitivity to valganciclovir, ganciclovir, aciclovir or valaciclovir or to any of the excipients
- History of illness or psychological or sensory abnormality likely to prevent the subject from fully understanding the conditions required for their participation in the protocol or preventing them from giving their informed consent
- Neutropenia (neutrophils < 500/mm3) or thrombocytopenia (platelets < 25,000/mm3) or anemia (hemoglobin < 8g/dl) identified on routine care samples taken on the day of inclusion
- Age < 18 or > 75
- Lympho-depleting inducing immunosuppressive treatment (antithymoglobulins)
- Pregnant or parturient or breast-feeding woman or absence of proven contraception
- Person deprived of liberty by an administrative or judicial decision or person placed under legal safeguard / sub-tutorship or curatorship
- Person participating in another interventional trial (Medicinal product)
This trial is currently available in France.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Demonstrate, in CMV+ transplant patients, the effectiveness of an immuno-guided preventive strategy compared to the universal prophylactic strategy, in terms of CMV infection in the 6 months following kidney transplantation.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Effectiveness of a preventive strategy for cytomegalovirus infection guided differently from a universal prophylactic strategy in kidney transplant patients - CYTOPREV
- Plain-language title
- Immune-guided prevention of cytomegalovirus infection after kidney transplantGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 26 March 2026